The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection

Vaccine

Volumn 35, Issue 1, 2017, Pages 10-18

  Jiaming, Lan ^a,c   Yanfeng, Yao ^a   Yao, Deng ^a   Yawei, Hu ^b   Linlin, Bao ^a   Baoying, Huang ^a   Jinghua, Yan ^b   Gao, George F ^a,b   Chuan, Qin ^a   Wenjie, Tan ^a  

^a BEIJING HOSPITAL   (China)

^b INSTITUTE OF MICROBIOLOGY   (China)

^c HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Animal model; MERS CoV; Mice; NTD; RBD; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; ALUMINUM; CD4 ANTIGEN; CD8 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 6; NEUTRALIZING ANTIBODY; RECOMBINANT AMINO TERMINAL DOMAIN SPIKE PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VIRUS SPIKE PROTEIN; CORONAVIRUS SPIKE GLYCOPROTEIN; RECOMBINANT VACCINE; VIRUS ANTIBODY; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; ASSAY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOMETRIC BEAD ARRAY ASSAY; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMORAL IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; INTRACELLULAR CYTOKINE STAINING; MIDDLE EAST RESPIRATORY SYNDROME; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TH17 CELL; TH2 CELL; VACCINATION; VACCINE IMMUNOGENICITY; VIRUS NEUTRALIZATION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CORONAVIRUS INFECTION; DISEASE MODEL; GENETICS; IMMUNOASSAY; IMMUNOLOGY; LUNG; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PATHOLOGY; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CORONAVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOASSAY; IMMUNOGLOBULIN G; LUNG; MICE, INBRED BALB C; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; SPIKE GLYCOPROTEIN, CORONAVIRUS; T-LYMPHOCYTES; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 84999816148     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.11.064     Document Type: Article

References (57)

1. [1] Zaki, A.M., van Boheemen, S., Bestebroer, T.M., Osterhaus, A.D., Fouchier, R.A., Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367 (2012), 1814–1820.
2. [2] van Boheemen, S., de Graaf, M., Lauber, C., Bestebroer, T.M., Raj, V.S., Zaki, A.M., et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio, 3, 2012 [pii: e00473-12].
3. [3] Peiris, J.S., Yuen, K.Y., Osterhaus, A.D., Stohr, K., The severe acute respiratory syndrome. N Engl J Med 349 (2003), 2431–2441.
4. [4] Zumla, A., Hui, D.S., Perlman, S., Middle East respiratory syndrome. The Lancet 386 (2015), 995–1007.
5. [5] Li, Y., Wan, Y., Liu, P., Zhao, J., Lu, G., Qi, J., et al. A humanized neutralizing antibody against mers-cov targeting the receptor-binding domain of the spike protein. Cell Res 25 (2015), 1237–1249.
6. [6] Tang, X.C., Agnihothram, S.S, Jiao, Y., Stanhope, J., Graham, R.L., Peterson, E.C., et al. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc Natl Acad Sci USA 111 (2014), E2018–E2026.
7. [7] Pascal, K.E., Coleman, C.M., Mujica, A.O., Kamat, V., Badithe, A., Fairhurst, J., et al. Pre- and postexposure efficacy of fully human antibodies against spike protein in a novel humanized mouse model of MERS-CoV infection. Proc Natl Acad Sci USA 112 (2015), 8738–8743.
8. [8] Ying, T., Du, L., Ju, T.W., Prabakaran, P., Lau, C.C., Lu, L., et al. Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J Virol 88 (2014), 7796–7805.
9. [9] Johnson, R.F., Bagci, U., Keith, L., Tang, X., Mollura, D.J., Zeitlin, L., et al. 3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys followingintratracheal inoculation of MERS-CoV Jordan-n3/2012. Virology 490 (2016), 49–58.
10. [10] Taguchi, F., Coronaviruses. Uirusu 61 (2011), 205–210.
11. [11] Li, F., Evidence for a common evolutionary origin of coronavirus spike protein receptor-binding subunits. J Virol 86 (2012), 2856–2858.
12. [12] Li, F., Receptor recognition mechanisms of coronaviruses: a decade of structural studies. J Virol 89 (2015), 1954–1964.
13. [13] Williams, R.K., Jiang, G.S., Holmes, K.V., Receptor for mouse hepatitis virus is a member of the carcinoembryonic antigen family of glycoproteins. Proc Natl Acad Sci USA 88 (1991), 5533–5536.
14. [14] Li, W., Moore, M.J., Vasilieva, N., Sui, J., Wong, S.K., Berne, M.A., et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426 (2003), 450–454.
15. [15] Delmas, B., Gelfi, J., L'Haridon, R., Vogel, L.K., Sjöström, H., Norén, O., et al. Aminopeptidase N is a major receptor for the entero-pathogenic coronavirus TGEV. Nature 357 (1992), 417–420.
16. [16] Lu, G., Hu, Y., Wang, Q., Qi, J., Gao, F., Li, Y., et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor cd26. Nature 500 (2013), 227–231.
17. [17] Raj, V.S., Mou, H., Smits, S.L., Dekkers, D.H., Müller, M.A., Dijkman, R., et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495 (2013), 251–254.
18. [18] Du, L., Zhao, G., Kou, Z., Ma, C., Sun, S., Poon, V.K., et al. Identification of a receptor-binding domain in the s protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J Virol 87 (2013), 9939–9942.
19. [19] Lan, J., Deng, Y., Chen, H., Lu, G., Wang, W., Guo, X., et al. Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen. PLoS ONE, 9, 2014, e112602.
20. [20] Tang, J., Zhang, N., Tao, X., Zhao, G., Guo, Y., Tseng, C.T., et al. Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus. Hum Vaccin Immunother 11 (2015), 1244–1250.
21. [21] Zhang, N., Tang, J., Lu, L., Jiang, S., Du, L., Receptor-binding domain-based subunit vaccines against MERS-CoV. Virus Res 202 (2015), 151–159.
22. [22] Guo, X., Deng, Y., Chen, H., Lan, J., Wang, W., Zou, X., et al. Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus. Immunology 145 (2015), 476–484.
23. [23] Kim, E., Okada, K., Kenniston, T., Raj, V.S., AlHajri, M.M., Farag, E.A., et al. Immunogenicity of an adenoviral-based middle east respiratory syndrome coronavirus vaccine in balb/c mice. Vaccine 32 (2014), 5975–5982.
24. [24] Song, F., Fux, R., Provacia, L.B., Volz, A., Eickmann, M., Becker, S., et al. Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus ankara efficiently induces virus-neutralizing antibodies. J Virol 87 (2013), 11950–11954.
25. [25] Malczyk, A.H., Kupke, A., Prufer, S., Scheuplein, V.A., Hutzler, S., Kreuz, D., et al. A highly immunogenic and protective Middle East respiratory syndrome coronavirus vaccine based on a recombinant measles virus vaccine platform. J Virol 89 (2015), 11654–11667.
26. [26] Lan, J., Yao, Y., Deng, Y., Chen, H., Lu, G., Wang, W., et al. Recombinant receptor binding domain protein induces partial protective immunity in rhesus macaques against Middle East respiratory syndrome coronavirus challenge. EBioMedicine 2 (2015), 1438–1446.
27. [27] Coleman, C.M., Liu, Y.V., Mu, H., Taylor, J.K., Massare, M., Flyer, D.C., et al. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine 32 (2014), 3169–3174.
28. [28] Volz, A., Kupke, A., Song, F., Jany, S., Fux, R., Shams-Eldin, H., et al. Protective efficacy of recombinant modified vaccinia virus Ankara delivering middle east respiratory syndrome coronavirus spike glycoprotein. J Virol 89 (2015), 8651–8656.
29. [29] Haagmans, B.L., van den Brand, J.M., Raj, V.S., Volz, A., Wohlsein, P., Smits, S.L., et al. An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. Science 351 (2016), 77–81.
30. [30] Wang, L., Shi, W., Joyce, M.G., Modjarrad, K., Zhang, Y., Leung, K., et al. Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun, 6, 2015, 7712.
31. [31] Zhao, J., Li, K., Wohlford-Lenane, C., Agnihothram, S.S., Fett, C., Zhao, J., et al. Rapid generation of a mouse model for middle east respiratory syndrome. Proc Natl Acad Sci USA 111 (2014), 4970–4975.
32. [32] Yang, Y., Deng, Y., Wen, B., Wang, H., Meng, X., Lan, J., et al. The amino acids 736–761 of the MERS-CoV spike protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents. Viral Immunol 27 (2014), 543–550.
33. [33] Guan, J., Deng, Y., Chen, H., Yin, X., Yang, Y., Tan, W., Priming with two DNA vaccines expressing hepatitis c virus ns3 protein targeting dendritic cells elicits superior heterologous protective potential in mice. Arch Virol 160 (2015), 2517–2524.
34. [34] Muthumani, K., Falzarano, D., Reuschel, E.L., Tingey, C., Flingai, S., Villarreal, D.O., et al. A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci Transl Med, 7, 2015, 301ra132.
35. [35] Falzarano, D., de Wit, E., Rasmussen, A.L., Feldmann, F., Okumura, A., Scott, D.P., et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med 19 (2013), 1313–1317.
36. [36] Omrani, A.S., Saad, M.M., Baig, K., Bahloul, A., Abdul-Matin, M., Alaidaroos, A.Y., et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis 14 (2014), 1090–1095.
37. [37] Du, L., Jiang, S., Middle East respiratory syndrome: current status and future prospects for vaccine development. Exp Opin Biol Ther 15 (2015), 1647–1651.
38. [38] Falzarano, D., de Wit, E., Feldmann, F., Rasmussen, A.L., Okumura, A., Peng, X., et al. Infection with MERS-CoV causes lethal pneumonia in the common marmoset. PLoS Pathog, 10, 2014, e1004250.
39. [39] Agrawal, A.S., Garron, T., Tao, X., Peng, B.H., Wakamiya, M., Chan, T.S., et al. Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease. J Virol 89 (2015), 3659–3670.
40. [40] Tao, X., Garron, T., Agrawal, A.S., Algaissi, A., Peng, B.H., Wakamiya, M., et al. Characterization and demonstration of the value of a lethal mouse model of Middle East respiratory syndrome coronavirus infection and disease. J Virol 90 (2015), 57–67.
41. [41] Raj, V.S., Smits, S.L., Provacia, L.B., van den Brand, J.M., Wiersma, L., Ouwendijk, W.J., et al. Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the Middle East respiratory syndrome corona-virus. J Virol 88 (2014), 1834–1838.
42. [42] Coleman, C.M., Matthews, K.L., Goicochea, L., Frieman, M.B., Wild-type and innate immune-deficient mice are not susceptible to the Middle East respiratory syndrome coronavirus. J Gen Virol 95 (2014), 408–412.
43. [43] de Wit, E., Prescott, J., Baseler, L., Bushmaker, T., Thomas, T., Lackemeyer, M.G., et al. The Middle East respiratory syndrome coronavirus (MERS-CoV) does not replicate in Syrian hamsters. PloS One, 2013, e69127.
44. [44] Sutton, T.C., Subbarao, K., Development of animal models against emerging coronaviruses: from SARS to MERS coronavirus. Virology 479–480 (2015), 247–258.
45. [45] Gretebeck, L.M., Subbarao, K., Animal models for SARS and MERS coronaviruses. Curr Opin Virol 13 (2015), 123–129.
46. [46] Lamirande, E.W., DeDiego, M.L., Roberts, A., Jackson, J.P., Alvarez, E., Sheahan, T., et al. A live attenuated severe acute respiratory syndrome coronavirus is immunogenic and efficacious in golden Syrian hamsters. J Virol 82 (2008), 7721–7724.
47. [47] Enjuanes, L., Dediego, M.L., Alvarez, E., Deming, D., Sheahan, T., Baric, R., Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease. Virus Res 133 (2008), 45–62.
48. [48] See, R.H., Zakhartchouk, A.N., Petric, M., Lawrence, D.J., Mok, C.P., Hogan, R.J., et al. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. J Gen Virol 87 (2006), 641–650.
49. [49] Spruth, M., Kistner, O., Savidis-Dacho, H., Hitter, E., Crowe, B., Gerencer, M., et al. A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses. Vaccine 24 (2006), 652–661.
50. [50] Lokugamage, K.G., Yoshikawa-Iwata, N., Ito, N., Watts, D.M., Wyde, P.R., Wang, N., et al. Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV. Vaccine 26 (2008), 797–808.
51. [51] Yasui, F., Kai, C., Kitabatake, M., Inoue, S., Yoneda, M., Yokochi, S., et al. Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. J Immunol 181 (2008), 6337–6348.
52. [52] Tseng, C.T., Sbrana, E., Iwata-Yoshikawa, N., Newman, P.C., Garron, T., Atmar, R.L., et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS ONE, 7, 2012, e35421.
53. [53] Takano, T., Kawakami, C., Yamada, S., Satoh, R., Hohdatsu, T., Antibody-dependent enhancement occurs upon re-infection with the identical serotype virus in feline infectious peritonitis virus infection. J Vet Med Sci 70 (2008), 1315–1321.
54. [54] Graham, B.S., Vaccines against respiratory syncytial virus: the time has finally come. Vaccine 34 (2016), 3535–3541.
55. [55] de Wit, E., Rasmussen, A.L., Falzarano, D., Bushmaker, T., Feldmann, F., Brining, D.L., et al. Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc Natl Acad Sci USA 110 (2013), 16598–16603.
56. [56] Munster, V.J., de Wit, E., Feldmann, H., Pneumonia from human coronavirus in a Macaque model. New Engl J Med 368 (2013), 1560–1562.
57. [57] Falzarano, D., et al. Infection with MERS-CoV causes lethal pneumonia in the common Marmoset. PLoS Pathog, 10, 2014, e1004250.